Administration of Autologous Bone Marrow-Derived Stem Cells for Treatment of Cerebral Palsy Patients: A Proof of Concept.
Himanshu Bansala b, Lipi Singhc, Poonam Vermab, Anupama Agrawala b, J Félix Leónd, I Birgitta Sundelle, Prasad S Kokaf
- aMother Cell, Anupam Hospital, Rudrapur, Uttarakhand, India
- bRegennMed Research and Therapeutics, New Delhi, India
- cSri Ganga Ram Hospital, New Delhi, India
- dAdvanced Health Institute, Puerto Rico, USA
- eDepartment of Anthropology, Wayne State University, Detroit, Michigan, USA
- fHaffkine Institute, Mumbai, India
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND: Stem cell therapy is a promising treatment for cerebral palsy, which refers to a category of brain diseases that are associated with chronic motor disability in children. Autologous bone marrow stem cells may be a better cell source and have been studied for the treatment of cerebral palsy because of their functions in tissue repair and the regulation of immunological processes. METHODS: mononuclear cells; 90% viability) into the subarachnoid cavity and rehabilitation. RESULTS: We recorded the gross motor function measurement scores, manual ability function measurement score, and adverse events up to 24 months post-treatment. The gross motor function measurement scores were significantly higher at month 6 post-treatment compared with the baseline scores and were stable up to 24 months follow-up. The increase in manual ability and communication function measurement scores at 6 months were not significant when compared to the baseline score. All the 10 patients survived and none of the patients experienced any serious adverse events or complications. CONCLUSION: Our results indicated that bone marrow derived MNCs are safe and effective for the treatment of motor deficits related to cerebral palsy. Further randomized clinical trials are necessary to establish the efficacy of this procedure.